NervGen Pharma Stock Forecast

Stock Price Forecast

According to 7 analysts polled by S&P Global, NervGen Pharma stock has a consensus rating of "Buy" and an average price target of $11.21. The average 1-year stock price forecast is 496.28% higher than the current stock price, while the lowest is $5.03 (+167.55%) and the highest is $18 (+857.45%).

Price Target: $11.21 (+496.28%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$5.03	$11.21	$10.1	$18
Change	+167.55%	+496.28%	+437.23%	+857.45%

Analyst Ratings

The average analyst rating for NervGen Pharma stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Jan '26	Feb '26	Mar '26	Apr '26	May '26	Jun '26
Strong Buy	1	1	1	3	2	3
Buy	3	2	3	4	4	4
Hold	0	0	0	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	4	3	4	7	6	7

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Ram Selvaraju H.C. Wainwright	H.C. Wainwright	Buy Reiterates $18	Buy	Reiterates	$18	+857.45%	Jun 25, 2026
Joseph Thome TD Cowen	TD Cowen	Buy Initiates n/a	Buy	Initiates	n/a	n/a	Jun 11, 2026
Justin Keywood Stifel Nicolaus	Stifel Nicolaus	Buy Reiterates $6	Buy	Reiterates	$6	+219.15%	May 21, 2026
Elemer Piros Lucid Capital	Lucid Capital	Buy Initiates $18	Buy	Initiates	$18	+857.45%	Apr 15, 2026
Andre Uddin Research Capital	Research Capital	Buy Maintains $5.5	Buy	Maintains	$5.5	+192.55%	Apr 10, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

n/a

Revenue Next Year

n/a

EPS This Year

-0.26

from -0.44

EPS Next Year

-0.38

from -0.26

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	-	-	-	-	-	-
Operating Income	-12.81M	-23.03M	-17.78M	-25.18M	-25.08M	-36.71M
Net Income	-12.73M	-20.72M	-22.38M	-24.25M	-44.12M	-32.63M
EPS	-	-	-	-	-0.44	-0.26
Free Cash Flow	-3.56M	-3.00M	-303.87K	-8.74M	-6.29M	-81.50M
No. Analysts	-	-	-	-	-	5

EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is CAD.

Revenue Forecast

Revenue	2026	2027	2028
High	n/a
Avg	n/a
Low	n/a

Revenue Growth

Revenue Growth	2027	2028
High	-
Avg	-
Low	-

EPS Forecast

EPS	2026	2027	2028
High	-0.23
Avg	-0.26
Low	-0.29

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-